# EDGAR Filing Document

**Accession Number:** 0002022416
**File Stem:** 0001178913-26-000289
**Filing Date:** 2026-2
**Character Count:** 25898
**Document Hash:** 1ab15d8944b8e3e2e187af2997990165
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-000289.hdr.sgml**: 20260203

**ACCESSION NUMBER**: 0001178913-26-000289

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 48

**CONFORMED PERIOD OF REPORT**: 20260203

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260203

**DATE AS OF CHANGE**: 20260203

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silexion Therapeutics Corp
- **CENTRAL INDEX KEY:** 0002022416
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42253
- **FILM NUMBER:** 26590440

**BUSINESS ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606
- **BUSINESS PHONE:** 972-8-6286005

**MAIL ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biomotion Sciences
- **DATE OF NAME CHANGE:** 20240506

?xml version='1.0' encoding='ASCII'?

------

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **February 3, 2026** 

**Silexion Therapeutics Corp**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Cayman Islands**<br>| **001-42253**<br>| **N/A** |
| (State or other jurisdiction | (Commission File Number) | (I.R.S. Employer |
| of incorporation) |  | Identification No.) <br>|

---

---

| | |
|:---|:---|
| **12 Abba Hillel Road**<br>**Ramat-Gan, Israel**<br>| **5250606**<br>|
| (Address of principal executive offices) | (Zip Code) <br>|

---

**+972-3-756-4999**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Ordinary Shares, par value $0.0135 per share**  | **SLXN**  | **The Nasdaq Stock Market LLC**  |
| **Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share**  | **SLXNW**  | **The Nasdaq Stock Market LLC**  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure.**

On February 3, 2026, Silexion Therapeutics Corp prepared a corporate presentation for use in meetings with investors as part of a non-deal roadshow. A copy of the presentation is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Form 8-K, including the presentation furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the presentation, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.

**Item 9.01 Financial Statements and Exhibits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

---

| | |
|:---|:---|
| [99.1](exhibit_99-1.htm) | [Corporate Presentation dated February 2026](exhibit_99-1.htm) |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL) |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SILEXION THERAPEUTICS CORP** | **SILEXION THERAPEUTICS CORP** |
| Date: February 3, 2026 | /s/ Ilan Hadar | /s/ Ilan Hadar |
|  | Name: | Ilan Hadar |
|  | Title: | Chief Executive Officer |

---

------

## Exhibit 99.1

------

**<u>Exhibit 99.1</u>**<br>

<br> ![](exhibit_99-1slide1.jpg)

Silencing Oncogenes at the Level of Gene Expression Nasdaq: SLXN Company Presentation \| February 2026

------

![](exhibit_99-1slide2.jpg)

Forward-Looking Statement The statements contained in this presentation that are not purely historical are forward-looking statements. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this presentation may include, for example, statements about: the future performance of the Company, including Silexion's projected timeline for regulatory approvals of its product candidates; and the Company's future plans and opportunities. The forward-looking statements contained in this presentation are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the items in the following list: Silexion is a development-stage company and has a limited operating history on which to assess its business; Silexion has never generated any revenue from product sales and may never be profitable; The approach Silexion is taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products; Silexion does not have experience producing its product candidates at commercial levels, currently has no marketing and sales organization, has an uncertain market receptiveness to its product candidates, and is uncertain as to whether there will be insurance coverage and reimbursement for its potential products; Silexion may be unable to attract, develop and/or retain its key personnel or additional employees required for its development and future success; Additional factors relating to the business, operations and financial performance of Silexion. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. 2

------

![](exhibit_99-1slide3.jpg)

Transforming treatment in historically "undruggable" cancers by tackling the driver of poor outcomes Lead product targets the most common oncogenic driver in human cancers, mutated KRAS gene Our technology, siRNA, isolates the oncogene, resulting in shutting down the cancer driving processes First generation (Loder) showed trend for extending patients lives in one of the most deadly cancers, pancreatic cancer Second generation (SIL204) broadens activity to additional cancers, optimizes stability, and incorporates cancer targeting Dual-delivery strategy maximizes the delivery to both important disease processes: primary tumor and metastases

------

![](exhibit_99-1slide4.jpg)

Agenda 4 Market and unmet need Our technology Advantages and differentiation of our technology / product First generation siRNA Phase 2 clinical results and preclinical results SIL204 SIL204 Phase 2/3 design SIL204 development plan and milestones achieved Patent protection for SIL204

------

![](exhibit_99-1slide5.jpg)

5 1. Lee, J.K. et al. NPJ Precis Oncol. 2022;6(1):91.; 2. Hirshberg Foundation for Pancreatic Cancer Research. Pancreatic cancer Facts. https://pancreatic.org/pancreatic-cancer/pancreatic-cancer-facts. Pancreatic Ductal Adenocarcinoma (PDAC) Colorectal Cancer (CRC) Non-squamous Non-Small-Cell Lung Cancer(Non-sq NSCLC) PDAC: 3rd leading cause cancer deaths today in the U.S.2, 2nd leading cause by 20302 % KRAS mutations1 Incidence USA+EU 92% ~200K 49% ~500K 35% ~400K Prevalent Cancers with KRAS Mutation we Target

------

![](exhibit_99-1slide6.jpg)

BRPC=borderline resectable pancreatic cancer; LAPC = locally advanced pancreatic cancer. Gemenetzis G, et al. Ann Surg. 2019;270(2):340-347; Kleeff J, et al. Nat Rev Dis Primers. 2016;2:16022. Local Metastatic 15-25% Resectable + BRPC ~30 LAPC ~50% Metastatic ~75% liver 6 Types and Relative Prevalence of Pancreatic Cancer

------

![](exhibit_99-1slide7.jpg)

Unmet Needs in Pancreatic Cancer (PC) 1. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. https://seer.cancer.gov/statfacts/html/pancreas.html. 2. Cancers 2021, 13(18), 4724; https://doi.org/10.3390/cancers13184724. 3. Gemenetzis G, et al. Ann Surg. 2019;270(2):340-347. 4. Alagesan, B. et al. AARC 2026. 5. Revolution Medicines November 2025 Company Presentation 7 There are no effective treatment options for our first intended indication LAPC Overall 5-year survival one of poorest U.S 12.8% 1 , KRAS G12D/V worst survival Resectable PC- Following surgery with perioperative chemotherapy, ~80% have metastases in 1 yr 2 Median survival LAPC 14-17mo.3,4 New small molecule RAS inhibitors efficacy promising and safety acceptable, but large gaps remain before the market is satisfied5 Severe or medically significant toxicities that typically requires active medical management and often hospitalization often include: Rash; fatigue; diarrhea; anemia; mucositis; neutrophils decrease

------

![](exhibit_99-1slide8.jpg)

8 Our Technology Lead Product: SIL204 First-in-class, isoform selective, pan KRAS silencer, stable siRNA with targeted delivery system Targets both the active and inactive forms of KRAS x

------

![](exhibit_99-1slide9.jpg)

Dual Administration of SIL204 Designed to Effectively Treat the Two Distinct Processes of the Disease: Primary Tumor and Metastases Intratumoral (endoscopic) SIL204 Targets Primary pancreatic tumor overcoming it's ECM barrier Systemic (s.c.) SIL204 Targets cancer cells shedding from primary tumor with metastatic invasions into liver, etc.

------

![](exhibit_99-1slide10.jpg)

10 Our Technology SIL204 binds to LDLs to high extent and carries the SIL204 systemically Pancreatic cancer cells have significantly higher LDL receptors than health pancreatic cells Enriched uptake by cancer cells compared to healthy Difference even more significant in metastatic pancreatic cells LDL targeting mechanism enriches siRNA in pancreatic cancer cells in the primary tumor and liver metastases Healthy pancreatic cell x siRNA % bound SIL204 95 siRNA-I 1.5 siRNA-V 5.1

------

![](exhibit_99-1slide11.jpg)

11 Advantages and Differentiation SIL204 positioned to become the most advanced RNA-interfering oncology product

------

![](exhibit_99-1slide12.jpg)

LODER (First generation siRNA) Phase 2 Clinical Trial Data Results

------

![](exhibit_99-1slide13.jpg)

Reduction in tumor size: Cohorts 1+2 First-Generation Mutant KRAS RNA Silencer (Loder) Led to Robust RECIST\* Antitumor Activity in mutant KRAS-Driven Locally Advanced Pancreatic Cancer LAPC=locally advanced pancreatic cancer. \*Response Evaluation Criteria in Solid Tumors. Overall response rate was confirmed by RECIST 1.1 of the target tumor, as analyzed by sites. Bar curves below the solid black line starting at y-axis -0.3 indicates criteria for positive RECIST response. Cohort 1: non-resectable LAPC, backbone chemo Gemcitabine Plus Nab-paclitaxel Cohort 2: LAPC or Borderline Resectable Pancreatic Cancer (BRPC), backbone chemo Gemcitabine Plus Nab-paclitaxel, Folfirinox or modified Folfirinox Best % change in tumor size from baseline Cohort 1+2 LODER+Chemo Chemo % RECIST\* Response 56% (10/18) 20% (1/5) % RECIST\* Response or tumor becomes resectable 67% (12/18) 40% (2/5) KRAS mutation subtype G12D G12V Chemo Loder R = Non-resectable tumor becomes resectable

------

![](exhibit_99-1slide14.jpg)

Cohort 1 LAPC KRAS_G12V or G12D Patients Treated with Loder Had 9.3 Months Improvement in Overall Survival 14 \* SoC (Control) OS consistent with recent trials for LAPC (Gemenetzis G, et al. Ann Surg. 2019;270(2):340-347). Hazard ratio (HR)=0.59, (95% CI, 0.18, 1.96, p=0.39) Time to death is slower, 41% reduction in the rate of mortality Patients living longer with Loder+SOC vs. SOC monotherapy Days Overall Survival in Cohort 1 SOC chemo median =13.4 mo.\* siRNA+SOC chemo median=22.7 mo.

------

![](exhibit_99-1slide15.jpg)

Safety From First Generation Loder Trial 15 Brinda Alagesan, B. et al. (2026) A Phase 2 Trial of an Extended-release siRNA Implant Targeting KRAS G12D/V in Locally Advanced Pancreatic Cancer. Clinical Cancer Research (in press) siG12D-LODER was generally well tolerated (includes intratumoral Loder rod administrations) No related Treatment Emergent Adverse Events (TEAEs) No meaningful observations in vital sign parameter nor any physical examination Independent Drug Safety Monitoring Board (DSMB) had no safety concerns nor restrictions

------

![](exhibit_99-1slide16.jpg)

SIL204 Second Generation Results

------

![](exhibit_99-1slide17.jpg)

17 SIL204 Knockdown of mRNA Transcript and Corresponding KRAS Protein Transfection with lipofectamine PK59 human tumor line G12D mutation Analysis at 72 hrs for mRNA and protein \*\*\*\* = p value ＜0.0001

------

![](exhibit_99-1slide18.jpg)

SIL204 (Second Generation siRNA)

------

![](exhibit_99-1slide19.jpg)

SIL204 Highly Effective with Broad Inhibition Across Human KRAS Mutations at Sub-nanomolar Concentrations SIL204 maintains and expands the silencing activity of first generation siG12DLoder 19 Model is a co-transfection setup where human KRAS is transfected in mouse Hepa1-6 cells with Dual-Glo reporter plasmids. Mutation NegativesiRNAControl WT KRAS KRAS G12D KRAS G12V KRAS G12C KRAS G12R KRAS Q61H\* KRAS G13D\* IC50 (nM) 0.16 0.19 0.44 0.47 0.59 0.24 0.37 MAX Inhibition (%) 0-7 91 90 80 73 71 88 88 IC50=half-maximal inhibitory concentration. \*G13D and Q61H tested in separate studies from the G12 mutations and wild type (non-mutated). Negative siRNA control collected over various studies

------

![](exhibit_99-1slide20.jpg)

SIL204 Inhibits Growth Human Tumor Cell Lines from Various Cancers with G12x and Q61x Mutations 20 Cell line KRAS mutation subtype IC50 (ng/mL) IC90 (nM) IC90 (ng/mL) A427 (Lung) G12D 537 70 1,079 PK59 (Panc) G12D 1,059 163 2,496 GP2D (Colon) G12D 445 56 852 HS766T (Panc) Q61H 476 124 1,907 AVG 613 103 1,583 CellTiter-Glo (CTG)) assay IC90 is the concentration for 90% inhibition of tumor cell growth, IC50 is the concentration to achieve 50% inhibition

------

![](exhibit_99-1slide21.jpg)

In Silico Thermodynamic Stability of Potential Duplexes Shows High Specificity of SIL204 for (K)RAS and Not (H)RAS/(N)RAS and No Off-target Binding SIL204 binding to KRAS G12V strong (-31.8 kcal/mole) No Off-Target Active Anti-sense Binding indicating low risk for side effects. No effect on regulatory RNAs Conclusions SIL-204 will silence the intended target KRAS mutations, but low risk for any effect with other proteins besides KRAS, with implications for better safety HRAS and NRAS very unlikely affected, continuous endogenous RAS activity Analysis conducted by Dr. James McSwiggen, McSwiggen Biotech Consulting LLC 21 21

------

![](exhibit_99-1slide22.jpg)

Intratumor SIL204 Significantly Reduced Tumor Volume and Growth While Increasing Tumor Necrosis (cell death) in Human Pancreatic Cancer Xenograft 22 \*p<0.05 ; \*\*\*p<0.0005 S.C. = sub cutaneous tumor, intratumor SIL204-SL administration. Day 1: Capan-1 (KRAS G12V) luciferase cells were xenografted to mice (s.c.) concurrently with SIL204 formulated in extended-release microparticles Day 15: tumors were removed, area determined and analyzed by histology for % necrosis from tumor center slice % Necrosis 5.5 4.5 3.5 2.5 1.5 0.5 Bioluminescence (106) Tumor area (mm2) \* \*\*\* % Area Necrosis at Day 15 Average Tumor Area at Day 15 Average Tumor Cell Number

------

![](exhibit_99-1slide23.jpg)

SIL204 Remains at Substantial Levels for >56 Days in Target Tissues in Rats 23 PK profiles of SIL204 after a single s.c. administration were determined in Sprague Dawley rats using a LC-MS/MS analytical method, in the plasma and after collection from kidney, liver, and skin. IC50/90 data from inhibition growth human PC tumor lines superimposed IC90IC50 Potential for treating micrometastases with clinical s.c. dosing on monthly basis

------

![](exhibit_99-1slide24.jpg)

Subcutaneous SIL204 in Orthotopic Metastatic Pancreatic Mouse Model 24 Tumors from Human tumor cell line Panc-1 harboring KRAS G12D mutation-luciferase Response analysis total bioluminescence. 30% and 50% decrease considered positive at Day 14. 30%=RECIST criteria Responder analysis Control High dose SIL204 \* (%) Human equivalent ~ mid-dose for trial Bioluminescent imaging of metastatic organs Bioluminescence

------

![](exhibit_99-1slide25.jpg)

SIL204's Anti-Tumor Activity Synergistic with Pancreatic Cancer Chemotherapy \* p<0.05, \*\*\*p<0.0005 Human pancreatic cell line Panc-1 (G12D) 25 \*\*\* \*

------

![](exhibit_99-1slide26.jpg)

Toxicology Extended single-dose GLP toxicity studies completed in 2 relevant species, aligned with ICH S9 guidance for oncology and confirmed by regulatory agency for initiation of Phase 2/3 clinical trial Established safety margins of up to 11-fold over the clinical starting dose. SIL204 was well-tolerated in both species with no test article-related organ toxicity or mortality observed. Adverse findings limited to non-adverse changes at local injection site, fully resolved at 1 month. No evidence of complement activation or immunotoxicity. Toxicology package for marketing approval planned for H2, 2026 Favorable Tolerability with No Systemic Toxicity or Organ Damage

------

![](exhibit_99-1slide27.jpg)

SIl204 Phase 2/3 Clinical Trial Segment 1: Phase 2/3 safety run-in Initiation Q2 2026 Expected completion Q4 2026 Segment 2: Phase 2 expansion Initiation Q4 2026 Segment 3: Phase 3 confirmatory Initiation Q3 2028 SIL204 administered intratumorally and systemically as an integrated treatment regimen (IR) Primary endpoint: Overall survival (OS) Secondary endpoints: Progression-free survival (PFS), overall response rate (ORR), QoL 2028 Trial Interim results Sample size adjustment

------

![](exhibit_99-1slide28.jpg)

SIl204 Phase 2/3 Development Plan and Milestones Achieved GMP API for Segment 1 manufactured, Segment 2 GMP manufacturing ongoing GMP formulation selected, manufacturing in process Toxicology for Segment 1 completed, for Segment 2/3 later in 2026 Scientific Advice from national European authority, with positive response Go ahead from ethics committee for Phase 2/3 from major oncology center Submitted to Israel MoH to initiate Phase 2/3 trial, waiting for response Submission to German MoH for Phase 2/3 trial planned 02/26 IND and CTA for additional EU countries, submission planned Q4/2026 Q1/2027 Start expanding trial to US, Canada, UK, additional EU countries, Australia

------

![](exhibit_99-1slide29.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Strategic Collaboration for SIL204 GMP Clinical Supply with Leading European Manufacturers Collaboration to leverage Catalent and Axolabs' experience in formulation development and manufacturing biologicals to further enhance SIL204's therapeutic potential through improved stability, bioavailability, and delivery precision. Catalent Limoges Facility A European Center of Excellence for clinical biologics formulation development and drug manufacture Axolabs Facility Leveraging expertise and large-scale nucleic acid production

------

![](exhibit_99-1slide30.jpg)

Intellectual Property Protection Exclusivity can be extended under country-specific regulatory-based extension rules. Submissions Term Entered national Phase world wide, SIL-204 as a composition and for use in treatment of pancreatic and other cancers (following successful USPTO review of PCT) U.S. Patent Application No. 19/443,507 CIP of U.S. Patent Application No. 19/138,670 Expected protection until 2043 plus estimated extension to 2048 siRNA against KRAS G12x for regional perineural invasion or pain associated with a solid tumor U.S. Patent Application No. 19/443,507 Pending US/EU, expected term till 2040 plus extension

------

![](exhibit_99-1slide31.jpg)

Highly Experienced Leadership Team Ilan Hadar, MBA Chairman and Chief Executive Officer Over 25 years of multinational executive managerial and corporate experience with pharmaceutical and high-tech companies. CEO PainReform ("PRFX"), CFO Foamix Pharmaceuticals Inc. (Currently "VYNE") Mitchell Shirvan, PhD, MBA Chief Scientific and Development Officer Over 30 years of experience in R&D, innovation and discovery in biotech companies. CEO Macrocure Ltd., Sr. V.P. R&D Foamix Pharmaceuticals Inc. (Currently "VYNE"), Sr. Director Strategic Business Planning Teva Pharmaceuticals Industries Inc. Mirit Horenshtein Hadar, CPA Chief Financial Officer Over 15 years of corporate finance experience in senior financial positions of public companies and privately held companies, in the pharmaceutical and high-tech industries. CFO Gouzy Israel ("GAUZ"). V.P. Finance Foamix Pharmacuticals Inc. (Currently "VYNE") 31

------

![](exhibit_99-1slide32.jpg)

World-Renowned Expert Scientific Advisory Board Eileen M. O'Reilly, MD Memorial Sloan Kettering, NY, NY Winthrop Rockefeller Endowed Chair of Medical Oncology; Co-Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research; Section Head, Hepatopancreatobi Hana Algul, MD Technical University of Munich, Germany chair for tumor metabolism; Director of the Comprehensive Cancer Center Munich, Germany at the Klinikum rechts der Isar, and Mildred-Scheel-professor and Milind Javle, MD The University of Texas & MD Anderson Cancer Center, Houston, TX Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine Philip A. Philip, MD Henry Ford Health, Detroit, MI Director, Gastrointestinal Oncology; Co-Director, Pancreatic Cancer Center; Medical Director, Research and Clinical Care Integration, Henry Ford Cancer Institute Talia Golan, MD Sheba Tel Hashomer Hospital,, Israel Head, Sheba Pancreatic Cancer Center - SPCC Matthew Katz, MD The University of Texas & MD Anderson Cancer Center, Houston, TX Department Chair, Department of Surgical Oncology, Division of Surgery and Professor. Andrew M. Lowy, MD UC San Diego, San Diego, CA Chief, Division of Surgical Oncology; Professor of Surgery Mark A. Schattner, MD Memorial Sloan Kettering, NY, NY Chief, Gastroenterology, Hepatology and Nutrition Service 32 Thomas Seufferlein, MD University Hospital Ulm, German Director of Internal Medicine University Hospital Ulm, President German Cancer Society

------

![](exhibit_99-1slide33.jpg)

SIL204First in class siRNA targeting KRAS mutation Phase 2/3 initiation for locally advance pancreatic cancer to be initiated Q2/2026 Isoform selective, pan KRAS silencer, stable siRNA with targeted delivery system Pipeline for additional cancers including CRC First generation (Loder) showed trend for extending patients lives in one of the most deadly cancers, pancreatic cancer Second generation (SIL204) broadens activity to additional cancers, optimizes stability, and incorporates cancer targeting Dual-delivery strategy maximizes the delivery to both important disease processes: primary tumor and metastases

------

![](exhibit_99-1slide34.jpg)

Thank You Nasdaq: SLXN Ilan Hadar Chairman & Chief Executive Officer email: ihadar@silexion.com Dr. Mitchell Shirvan Chief Scientific and Development Officer email: mshirvan@silexion.com Mirit Horenshtein Hadar, CPA Chief Financial Officer email: mirit@silexion.com

------